Natco Pharma – Affordable Medicines
Natco
Natco Pharma Limited is an Indian pharmaceutical company founded in 1981 and headquartered in Hyderabad, Telangana. Its shares are listed on India's NSE and BSE stock exchanges.
Oncology is Natco's main focus. The company makes generic cancer medicines — targeted, hormonal and chemotherapy drugs — including complex molecules that require in-house development of both the active substance and the dosage form. Beyond oncology, its portfolio covers hepatitis C, multiple sclerosis and other chronic conditions.
Natco is known for landmark cases in access to treatment. In 2012 it received India's first compulsory licence, to make a generic of sorafenib (the original is Bayer's Nexavar), cutting the cost of kidney and liver cancer treatment many times over. In 2014 Natco signed a licensing agreement with Gilead to produce sofosbuvir for hepatitis C in developing countries.
The company manufactures both active substances and finished medicines at its own plants in India. Natco products reach markets in the US, Europe, Latin America and Asia through partners and subsidiaries, including in the US and Brazil.
Unifarm carries Natco's oncology and haematology medicines: Veenat (imatinib), Capnat (capecitabine), Letronat (letrozole), Anastronat (anastrozole), Carfilnat (carfilzomib), Thioplan (thiotepa), Desifer (deferasirox) and more — see the full list below.